Unpaused, an anthology on Amazon Prime Video, features stories by directors Nikkhil Advani, Tannishtha Chatterjee, Nitya Mehra, Avinash Arun, and Raj and DK.
Lupin launches antiviral drug Favipiravir under the name Covihalt to treat mild to moderate COVID-19 infection
The Covihalt tablet will be available in 200 mg tablets in a strip of 10 and will cost Rs 49 per tablet in India.
Lupin Q4 results: Consolidated net profit rises 35% to Rs 390 cr; income from operations marginally down
Drug firm Lupin has reported a 34.55 percent rise in its consolidated net profit to Rs 389.63 crore for the quarter ended March 2020 mainly on account of robust sales in the domestic market and lower tax expenses
Drug maker Lupin on Thursday said the US health regulator has closed the inspection of its manufacturing facility in Pithampur, Madhya Pradesh
Pharma major Lupin on Wednesday said it has received an establishment inspection report (EIR) from the US health regulator for its Mandideep Unit II facility in Madhya Pradesh
Lupin gets EIR from USFDA for Nagpur plant; MD says committed to enhance compliance, quality standards at all sites
Drug maker Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Nagpur
Pharma major Lupin has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Aurangabad facility.
Power sector stress spreads to new areas, corporate India’s poor Q3 numbers just a trailer; all this and more on Moneycontrol Pro
The Ujwal Discom Assurance Yojana (UDAY), which was launched more than four years ago, has failed to revive the electricity distribution sector to the desired strength.
Budget overhang, RBI policy, third quarter earnings to decide market course this week; investors disappointed: Analysts
Giving a thumbs down to the Budget, the market benchmark Sensex logged its biggest single-day plunge in more than a decade on Saturday after Budget presentation.
Lupin to divest entire stake in Japanese subsidiary Kyowa Pharma to PE fund Unison Capital Partners for over Rs 3,702 cr
Under the terms of agreement, Lupin's subsidiary Nanomi BV will divest its entire stake in Kyowa to Unison's entity Plutus Ltd for an enterprise value of JPY 57,361
The scrip declined 2.49 percent to close at Rs 743.95 on the BSE. During the day, it dropped 5.43 percent to Rs 721.50
Lupin gets more time from govt to complete project in Indore SEZ; vows to begin production before March 2020
Lupin is setting up its pharma unit in Indore SEZ to manufacture pharmaceutical formulations metered dose inhalers and dry powder inhalers.
Lupin seeks more time from govt to complete project in Indore SEZ; board of approval to take up matter on 22 April
Lupin received the LoP on 12 April, 2016. It has already received two extensions, valid till 11 April this year.
Lupin reports Rs 152 cr loss in Q3 on one-time provisioning for litigation expenses; income from operations rise
On 12 December, 2018, the General Court of the European Union delivered its judgment concerning Lupin's appeal against the European Commission's 2014 decision in a litigation related to Perindopril.
Lupin gets Establishment Inspection Report from USFDA for Pithampur facility unit; stock falls 1.88%
Drug firm Lupin on Monday said it has received an Establishment Inspection Report (EIR) from the US health regulator for a unit of its Pithampur facility in Madhya Pradesh.
Shares of Lupin were trading at Rs 854.00 per scrip on the BSE, up 1.09 percent from its previous close.
Earlier in May, in a regulatory filing Lupin had said that the US health regulator had completed inspection of the Nagpur facility without making any observations.
Lupin's US arm is recalling 11,706 bottles of Lisinopril tablets, used for treating hypertension, from the American market, USFDA said.
"The first quarter of FY2019 has been subdued, primarily on account of the US and Japan," Lupin Ltd Managing Director Nilesh Gupta said in a statement.
Q1 results, global cues, crude prices, monsoon session of Parliament to affect affect markets' moves this week
Market analysts opined that crude oil prices and developments in the monsoon session of parliament will also affect the markets' movement.